Glycogen synthase kinase-3 (GSK-3) inhibitors are a class of serine/threonine kinases and classified further into the GSK-3α and GSK-3β forms.77 Further, GSK can act as a tumor suppressor in many cancer types such as lung,78,79 breast,80–82 skin,83,84 pancreas,85–88 hepatocellular carcinoma89,90 and leukemia.91,92 However, to date, no USFDA-approved GSK inhibitor is available in the market for the treatment of cancer. Here, MARK2 is linked to cancer.